Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.
Read more(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day.
Read more
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read more
June 30 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Read more(Alliance News) - AstraZeneca PLC on Thursday said its antibody Imfinzi, when used with chemotherapy, significantly improved responses in a form of cell lung cancer.
Read more(Sharecast News) - Pharmaceutical giant AstraZeneca has received positive results from a planned interim analysis of the AEGEAN Phase III trial on its resectable non-small cell lung cancer drug.
Read moreNuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."
Read more(Alliance News) - Stock prices in London opened higher on Monday amid hopes of less aggressive monetary policy tightening by central banks, while Biffa shares fell after a delay to the publication of its annual results.
Read more(Alliance News) - AstraZeneca PLC said on Monday that its breast cancer treatments, Lynparza and Enhertu, have been recommended for approval in the EU.
Read more(Alliance News) - Stock prices in London are seen opening higher on Monday following a strong close in the US on Friday and a rally across Asian markets, amid gatherings of world leaders and central bankers at separate meetings in Europe this week.
Read more(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza, its HER2-negative high-risk early breast cancer drug, has been recommended for marketing authorisation in the European Union after demonstrating "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.
Read moreMANNHEIM, June 24 (Reuters) - Roche remains sceptical about investing more in antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs, even as they attract heightened attention in the pharmaceutical industry.
Read moreMANNHEIM, June 24 (Reuters) - Roche remains sceptical about investing more in the field of antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs due to their precision, even as the field attracts heightened attention in the pharmaceutical industry.
Read morePARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.
Read moreJune 23 (Reuters) - Valneva's COVID-19 vaccine was endorsed by the European Medicines Agency (EMA) on Thursday, although the French company's contract with the European Commission to supply the dose hangs in the balance.
Read more
Last checked at